Notably, an IL-2Rα-biased agonist upregulated CD25 expression on tumor-specific T cells, and tumor-specific CD8 + T cells became more susceptible to the agonist via positive feedback and restored the IL-2 signature. This evidence concerns the gene CD8A and neoplasm.